SLC34A1

Across TCGA pan-cancer cohorts, SLC34A1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SLC34A1 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SLC34A1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC34A1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, ACC, and COAD are the cancer types where SLC34A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.230	0.712	<.001	33	view →
ACC	DFS	Median	III,IV	0.010	0.458	<.001	21	view →
COAD	OS	Median	All	0.479	0.873	.009	15	view →
SKCM	OS	Median	III,IV	0.211	0.729	<.001	7	view →
PRAD	DFS	Median	All	0.085	0.774	.002	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.830	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SLC34A1–BLCA (OS)

Open the BLCA breakdown →